<SEC-DOCUMENT>0001193125-12-258375.txt : 20120604
<SEC-HEADER>0001193125-12-258375.hdr.sgml : 20120604
<ACCEPTANCE-DATETIME>20120604133324
ACCESSION NUMBER:		0001193125-12-258375
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120531
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120604
DATE AS OF CHANGE:		20120604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		12885453

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d362430d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>May&nbsp;31, 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. PHARMA,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code:&nbsp;(650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01&nbsp;Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On May 31, 2012, A.P. Pharma, Inc. announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of
Clinical Oncology&#146;s (ASCO) 2012 Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01&nbsp;Financial Statements and Exhibits. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Document Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on May 31, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. PHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: June 4, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d362430dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g362430gra.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>A.P. Pharma Announces Study Finding Continuous Exposure to a </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5-HT3
Antagonist Using APF530 Provides Better Emetic Control </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#150; Phase 3 Data Abstract Accepted by American Society of
Clinical Oncology for </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Publication at Annual Meeting</I><I> &#150;</I> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; May 31, 2012 &#150; A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that an abstract
analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology&#146;s (ASCO) 2012 Annual Meeting. APF530 is the Company&#146;s lead product candidate being
developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). The abstract concludes that continuous exposure to a 5-HT3 receptor antagonist, through the administration of an extended-release
formulation such as APF530, results in better emetic (nausea and vomiting) control than administration of a standard, short-acting 5-HT3 receptor antagonist. The title of the abstract is: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effect of continuous exposure to serotonin receptor antagonism on delayed emesis: An analysis of 1,535 patients in two randomized
clinical trials with granisetron (G), APF530, and palonosetron (palo). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abstract No.: e19635 </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authors: Harry Raftopoulos, Erin O&#146;Boyle, Richard J. Gralla, Martin Rosenberg, John Barr </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The full abstract is available on the ASCO website, <U>here</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead product, APF530, is in
development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company&#146;s proprietary Biochronomer<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single
subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by physicians based on a
well-established record of safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> polymer-based drug delivery technology. The Company&#146;s primary focus is on its lead product, APF530, for the
prevention of CINV. A.P. Pharma received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional research and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-<I> more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B></B><I></I><B></B><I>A.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Anatagonist Using APF530 Provides Better Emetic Control</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Page&nbsp;2</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>&nbsp;&nbsp;</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">development programs that utilize its bioerodible, injectable and implantable delivery systems. For further information, please visit the Company&#146;s web site at <U>www.appharma.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations
Contact:</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office
Phone: 646-597-6979 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mobile Phone: 917-282-3242 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Email: <U>mrice@lifesciadvisors.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact:</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President, Chief Executive Officer and Chief Financial Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g362430gra.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g362430gra.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`.0"Q`P$1``(1`0,1`?_$`)D``0`"`@,!````````
M```````%!@('`00(`P$!``,!`0$```````````````,$!0$&`A```0,#`P($
M`@<%"`,``````0(#!``1!1(&!R$Q05$B$V$4<8&1H;$R0F)RHB,(P5*"DK(S
M%19#<R01``("`@$$`0,#!`,!```````!`@,1!`4A,4$2$U%A(G&!,O"14B/!
MT105_]H`#`,!``(1`Q$`/P#U30"@%`16?W/@\!&,G+3&XK7Z0L^M1\DH'J4?
MHJ2NF5CQ%9(K;H5K,G@U3N/^HII"U-8#&%VW1,F62@'XAM/J^TUKT\.VLS>#
M&V.:P\062E2^;N19+FI,UN*F_1###8'VK"S5^/$T+NLF?+E]B7V,8W-/(C#@
M6<FEZW_C=8:*3_E"3]]'Q5+[+`7+7+NS9W'7-L3/RV\5F640<F\=+#R"?8=5
M_=Z]4J/@#63N<8ZE[1ZHU]'E5:_6721M,6O\:RS7.:`4`H!0"@%`*`4`H!0"
M@%`*`4`-`8E0M:]K4&#57(O-47#EW&[>TS,DBZ'I1]3+)\OVU#R[5JZ7&NS$
MI](F3N\FH94.K-!Y;+Y3+353<G*<ERE]W7#<CX)'9(^`KTM-,8+$4>5NNG.6
M9,ZH6;DGJ:D:/B,GDSU#Q!KYP??MA8.-*B+_`(TR<]&S)M;R74N-**'6R%MK
M'0A23<'[:Y))K#/JO.5@]A;5R:\EMO%Y!S_<E1FG7/WE)!5]]>(NAZS:^Y[F
MB?M!/ZHE=5^QJ/),#^46K@*-A>36\KON7M:-!44PR[[LXN#3_*L"=%O%1MWJ
M[;I^M2L;[^"C5O*=SK2[>2\WN15,O'.KK0'`/QH@"H`UP'`4//O0&6I/G70<
M7`Z7K@%[=+UT`G[^]`<W%N]`<7^)KIPY5>W2N'33'+')CCD__J6"EHC+<6&<
MGE"HI2WJ-BVE0[6'YU?56QHZ7XNR2S]$8G(;W55P?7RR!@[#XK;R3&#G;BD2
M\Q(4EO5$`$<.KZA(5I4._F:LSW-AQ<U'$400T]=/T<VY,I?(.T!M3<SV)2^9
M#(0AYET@!10L=`H#I<$5I:6R[JU)K!D<AK*FSU1`Q([K\QF,U_N/N(:3]*U!
M(_&K%D\1;*U4<S2-M[FXTXSVQ*AC-9J4REULER(D!QU9Z#4-*?2@=:PJM[8M
MSZQ1Z"WC]>IKWDR'Y(XYPV$P<'<.WY;DK$2RE"DN*"[>X+H6E0`Z&WC4^AO3
MG-PFNJ(-_1A7!3@WZLUTVEQ9"&DDJ4;(`[DJZ`?;6K+HLF1#+['H7?&Z\KL#
M9&WHF/#?_(*0W'4'4ZP$M-#7Z01^HBO,:NNMBV3?8]7M;+UJHI=R%S6]N:(F
M(:S[D%B#BD(0IQ)0A;GJL-:T$ZDA7P[5-7JZTI^B?4KV[6S&/NUB)L+9N]49
M[92=P/-AAUI#IEM)_*%L`E5K^![BL_9UOCM]#3UMKY*O<TIQD]OB1D\QD=M0
M&Y$Z82ER?)(#3(<67%#K^92NE;F]&I1C&;Z+P8''RN<I2@L^WDO?%G(6[LIN
MR=M[<*FWG(Z'%>ZA*4E#C2PE2;H])2;U0WM.N-:LAV9H<?N6SM=<_!8-[Y?D
M8Y=C#[5QS:6W6_<<R[Y"FTV/5-CT21\>]5=:NGU<K'U^A:VK+G)1K7[E5P&^
M>0<5R%%VMN1]B:F4I*5*;0D%(<25)4E20GRZ@BKENM3.EV5IK!3JV[H7*JQI
MY)/F;D+-[8EXN)B'DM.2`MV22A+AT)(2D`*[7-1<=J1M4G+P2\ENRI<5'R?3
M:VY]^RD9C<.X&#CL(Q"4[CXJD)25*%SJ5^N]AX^=<OHJ3C"#S+/4^J-BUQE.
M?XQQT*MM+=G,VZ\?*_XQV.EM*_7D7D(;"+)O[3=@;GKU-JM;&OK4R7MG]"GK
M;.U=%^N/U,-E[^Y7S!F86`&)TYM77(2-*1'2"4J*M(`7<CTUW:TM>O$WT7T&
MIM[-B<%AR^IW]A[OWZCDI>V,Y.$U`#J9"0E)2A2$:TJ0I(3T\*^-G6I^#Y(+
M!]:FU<K_`(YO/U+OOR3R(J5#Q^U([3;,D*^9RCA2?9*?`I5V%O'K6?K*E9=G
MCP:>T[GA5_W*''W'R+MGD#$X',9EO*L9!;:70`"D(<5I/@E25`UHRIHLIE.$
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M:\G..H;V$FNQWN99TC)<CRX[(*W6`U"8:`]15:]@/BI=0\6E"C+)N4DY7X7Z
M%NY)A28&P=L[)C-JDY9T-N.1FAJ79E!*[`?M*M]54]*2E=.U](E[?CZTPI7\
MBO\`$W'F3E[N2O+Q'(T?#E+[[+R2DJ=4+LH(/T:JL\CO15>(O/L5N-T9.?Y+
M'K_2)KF-Y.6Y*V]@E+`9:]GW-1L`7W;JO_A0*K\<G"B<D3\G)3V(0?9%MYPW
M#`QNRG\=K`EY+2RRR#U]M)"EK^@`6JIQE+G;[>$7>5O4*7'RR#:8D[6X$>#P
M+<N>V3I/0@S%@)'TZ#4TI_+N)KLF5U!TZ;3[M$UPQ&:P_&IR#HT^\I^:H^:$
M"R?N14/)2][\?L6.+A\>OG]RK\%ELO[FW5+_`"MI)6OX**GW/N`JURG:%:*O
M%O+G8983([QY+E3Y:\TK;^W82PGV8QTK(/J&I5Q<Z>I)I9"O522C[39RN=NT
MVW+T@B'XMQ,23RP^J+(<FP<6'G&)3JM:W+?RTK*O&Y)M4N_8UKK*PWX(-"O.
MTVG[)>25W(G_`+#SU!A&RX^/+25H(N+,I]Y7\2JCI_UZC?U)K_\`;MJ/^/\`
MQU+OS3DQ`X^GH!LN8IN,FWDI0*OX0:H\;#VN7VZE_E+/6A_<BMCA.V^%G,B1
MI<7&?F'SU.W"/[*DV?\`9LX^Y#J+XM3/V9T?Z>H/L;>RN8>'JDOZ-1[Z6$74
M?M4:DY:69QBO"/CAXM5RF_+(OA@#*;XW)N5_JE`<4E7_`+G"K_0BIN1_&J$%
MW(>-7M;.QF./R^<Y+SF2^9S:\)MN`-9887[:U-E1"2I5Q>X3=1/04G7'7A'$
M?:;$+I;,WF7K!$+LO#865S!'C8=Y<O%0%J?;E.J+BG/9;ZKU6%P7#TJ?8MDM
M7\EAR(-6J+V<1>4CT=UKS6&>G/.'/69=G[U^0"KLXME"$I\-;HUK/X"O4<15
MZU>W^1Y3F+/>WU_Q(SCWDQ_:")T54%,^%.*5.-E6A25!.D];*N"/"I-W0^9I
MYPT1Z?(?#E8RF2^*YK:PTIPXO;,*'!<%O8:)0X57OJ6YIZ]/"U03XGW7Y3;9
M-#EU"7XP2(+9W(<C;FX,EFODD39.1U7#CA3H"U^XH`@&]6=G15L(QSCU(-3=
M==DI8_D7+A/7E=Z9W<LL`*0TMQ2NX2N0O40#\$IJAR?X5QK1H<;^5LK'_62/
M/.*Q)=D/;?@R\DA:Q%R2AI4$:CHU`)))"?)521XK,5^3Q]""7+)2>8IR79D?
MLC<N[L[R4UEVXZ<GDE)4A(<*FV([*A8K]-]*4B]AXFI-O7JKH],X1'I[%ENQ
M[8RSTBQ%::+CB4)2Z\0IY:1;4H`)N?'L*\WD]2DD:!3@HN_^7<VQ(=<1#9#H
M2\T0%(]@):;()O\`JZUO_*]?6BUW9YWXEL;,L]O^B[83@S#1<FU/S&1DYI<<
M@LLR+!'3MKZJ*K>5[52MY.4EB*4?T+]?%0C+,I.7ZEJWQLR+NW#MXM^4[#8;
M=2Z2R$DDH!"00H6MUJGK;#JG[)9+>UK*Z'JW@^Z-IQ6]GC;##[C481?E!(2$
M^X$D64KRN;UQWOY/=]\GU\"^/X\],8.GM'CW$;;P$O",NN2X\U2S(6[I"R'$
MZ+>D`=!7U?MRMG[/NB/7U(U0<%U3*I#_`*?MOQWU@Y6>N"HW5#2I+:5@=DK4
MD74!5R7*S:QZK/U*D>(@G_)^OT+)LGC+![0FS)D!YYU4M`;*7M!"$)45`)T@
M'QJML[LKDE)=BUJZ4:6W%]S+#<:XC&;NE[I3)??GR_<*D.E/MH]VU](`!Z`6
M[UR>Y*5:K\([7IQC8[/+.WOC8^.W?`8A3Y#[###A='RY2DJ5I*>NH*[7KYU]
METO*/K9UE='#9GE-F8S(;2&V%.NL0`TVQJ:(#FAJQ`N01UMUZ5\POE&SW\G;
M->,J_C\&6!V;C<'ME6WH;CORJTNI4\HI]V[M]2K@`7Z].E=MV)63]WW.5:T:
MZ_1=CK[,X_PNT8DJ+`6Z\B8H*>4^0I1`3I`ND)Z6KZV-J5K3?@YKZL:DTO)6
ME<`[+,Y<DOS!'6HJ,-+H2W8F^FX3JT_"]6/_`*=OKCH5GQ53EGJ3NU^+]L;:
MS+V5QGO)>>0IL-+7J;0E1"K(%KCMYU!?NV6QQ+P3T:-=4LQ1;[?&JG0N'EKF
M:&]$Y#RBEW`DEI]H^:%-A/\`J2:];Q4DZ4OH>/Y>+C<_N4>Y\ZTS)RP23W-Z
M`R'1`[?17RR1/")7#[HW#AXTF)C)KD6/,'_T(;T^OIIZDB_8U6MUH6-.2S@M
M5;%D$XQ?<DME<>;BW7)2F"U[4!!L]D'!9M(\0D_K5\!46SNPI77N2ZG'V6O/
M@]*;,V1AMJ8T0\>W=Q=C)E+`+CJO-1\O(=A7E]C9E;++/5ZVM&J.$6"W4^50
M%@AL+M';>&F/R\9CVHLF5?YAY`.I=U:C<DG]76I)W3DL-]$0UT0@VTNI-5&3
M"P\J`4`L*`6%`+"@%`*`4`H!0"@%`*`HG*7&D?=\%MZ.XF/F(@(C/*'I6D]2
MVY;K8^!\*O:6\Z'VRF9^_HJ^/TDCSYF-A;OQ#RFYV+D)";_SFT*=;5^ZIL*K
MTE6]7-=&>7LX^R+ZID8G!YE:@E,"2I1[`,.W/\-2/:@O*(O_`!S^C_LRR83B
M7?F64/:Q:XS9[O2R&4CZE>H_4*K6\E3#SG]"W1Q5L_&#:>TN`,-"6B3N"0<D
M^.ORS=VXX/Q_4O\`"LC8Y:<^D.B-K6X>$.LW[,VI&AQ8K"(\9I++#8TMM-@)
M2D#P`%93DV\ON:ZBDL+L?:N'10"U`*`4`H!0"@%`*`4`H!0"@%`*`4`/A]-`
L<#\IH&$T.F/ZZX/!D.]=.'-`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
